Cookies on this website

We use cookies to ensure that we give you the best experience on our website. If you click 'Accept all cookies' we'll assume that you are happy to receive all cookies and you won't see this message again. If you click 'Reject all non-essential cookies' only necessary cookies providing core functionality such as security, network management, and accessibility will be enabled. Click 'Find out more' for information on how to change your cookie settings.

The University of Oxford in collaboration with the University of Maryland School of Medicine has begun recruiting for a Phase I/II trial of a new paratyphoid vaccine in human volunteers in Oxford. In the first study of its kind, after vaccination volunteers will be 'challenged' with paratyphoid to see whether the vaccine can prevent infection.

The Vaccine Against Salmonella Paratyphi (VASP) study will assess the immune response, efficacy and safety of a new vaccine, CVD 1902, against paratyphoid fever (a form of enteric fever similar to typhoid), which is given by mouth as a drink. CVD 1902 was developed by a team of scientists at the Center for Vaccine Development and Global Health (CVD) of the UMSoM. The use of a human challenge model to do this will allow an understanding of the vaccine's effectiveness without having to immunise thousands of people.

A planned sample of up to 76 participants – aged 18 to 55 and in good health – will be randomised to either receive two doses of the new paratyphoid vaccine or a placebo given 14 days apart. All participants will then be challenged with paratyphoid bacteria to see if they are protected against infection.

Following challenge, participants will be monitored closely and treated with antibiotics as soon as they show signs of infection, or after two weeks if they do not show any signs of infection. Results are expected in 2023.

Professor Sir Andrew Pollard, Director of the Oxford Vaccine Group and Chief Investigator of the trial, said: 'Vaccines are urgently needed to prevent the 3.3 million cases of paratyphoid fever that mostly affects school-age children in South and South East Asia. This first human challenge study to evaluate a paratyphoid vaccine will bring us a step closer to reducing the burden of this affliction in the world.’

'Enteric fever is a common infectious disease worldwide spread by drinking contaminated water. Although mainly caused by Salmonella Typhi a quarter of cases are due to another organism Salmonella Paratyphi. A new vaccine has recently been approved for typhoid, but no vaccine currently is licensed for paratyphoid. Due to increasing antibiotic resistance, the need for vaccines against these bacteria are desperately needed', Professor Brian Angus, Principal Investigator of the trial.

The full story is available on the University of Oxfore website

Similar stories

Pilot study detects diverse DNA in ingredients of falsified tablets

A recent multidisciplinary pilot study, originating from LOMWRU and the Medicine Quality Research Group of IDDO and MORU, investigated whether bacterial, plant, fungal and animal DNA in the ingredients and from the environment (eDNA) could be detected from falsified (aka counterfeit) tablets.

Expert Comment: Biotechnology allows us to make unprecedented interventions for conservation

In the wake of high-profile reports on the devastating toll human activity has had on global biodiversity, nations are expected to adopt the Convention on Biodiversity post-2020 framework that outlines measures to ensure humans live in harmony with nature.

Researchers call for antimicrobial resistance surveillance to be improved

The number of studies reporting antimicrobial resistance (AMR) data has increased in Africa, South and South East Asia according to new research in the International Journal of Infectious Diseases.

Meta-analysis informed the updated WHO guidelines for treatment of uncomplicated malaria in the first trimester of pregnancy

A new WWARN meta-analysis, commissioned by the World Health Organization and which informed a change to its treatment guidelines, has been published in The Lancet. The study provides compelling evidence that artemether-lumefantrine should now replace quinine as the treatment of choice in the first trimester.

Bacterial infections linked to one in eight global deaths, according to GRAM study

Data showing 7.7 million deaths from 33 bacterial infections can guide measures to strengthen health systems, particularly in low-income settings

GRAM visualization tool tracks country-level AMR and related metrics

Interactive app allows users to explore data underlying estimates of global AMR burden